Cubist, Astellas deal

Cubist acquired rights to the cephalosporin antibiotic ceftolozane in undisclosed Asia-Pacific and Middle East territories from Astellas. The pharma will receive $25 million up front and sales of ceftolozane/tazobactam ( CXA-201) in the newly obtained territories will be counted towards commercial milestones and royalty terms of the companies' original agreement. According to Cubist's 2012 10-K, Astellas was eligible for up to $40 million remaining in milestone payments, plus tiered single-digit royalties. With the acquisition, Cubist now has worldwide rights to develop and commercialize ceftolozane and CXA-201. ...